UPLD:NASDAQUpland Software, Inc. Analysis
Data as of 2026-05-07 - not real-time
$0.97
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Upland Software trades at $0.97, far below its DCF‑derived fair value of $8.36, implying an upside of roughly 285% and positioning the stock as deeply undervalued. The company generates solid operating cash flow ($25.8 M) and free cash flow ($33.7 M) despite a recent revenue decline of 27.5%, and its gross margin remains robust at 74.8%. However, profitability is weak (negative net margin –17.9%) and leverage is extreme, with a debt‑to‑equity ratio of 291%, raising concerns about balance‑sheet resilience. Technical indicators show the price above the 20‑day and 50‑day SMAs, a bullish MACD crossover, but an overbought RSI of 71.7, suggesting short‑term pressure may emerge. Recent news adds mixed signals: an earnings miss and a Nasdaq bid‑price deficiency notice increase near‑term risk, while analysts maintain a Buy rating with a $3 target and note free‑cash‑flow outperformance, supporting a longer‑run upside narrative.
Given the extreme volatility (125% 30‑day) and a beta near 2, the stock is highly sensitive to market swings, and the current market sentiment is in the “Extreme Greed” zone. The combination of a distressed balance sheet, high beta, and potential delisting risk elevates the overall risk profile, but the massive valuation gap and positive cash generation provide a compelling case for investors with a higher risk tolerance to consider accumulating the shares for the medium to long term.
Given the extreme volatility (125% 30‑day) and a beta near 2, the stock is highly sensitive to market swings, and the current market sentiment is in the “Extreme Greed” zone. The combination of a distressed balance sheet, high beta, and potential delisting risk elevates the overall risk profile, but the massive valuation gap and positive cash generation provide a compelling case for investors with a higher risk tolerance to consider accumulating the shares for the medium to long term.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Recent earnings miss and overbought RSI signal potential pullback
- Nasdaq bid‑price deficiency notice raises near‑term delisting risk
- Current price near resistance at $1.06 with limited upside in the next weeks
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong free cash flow generation despite revenue decline
- Analyst consensus remains bullish with a $3 price target
- Significant valuation upside (>200%) relative to DCF fair value
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value of $8.36 suggests massive long‑run upside
- AI‑powered SaaS platform positions the company for secular growth
- Resolution of bid‑price deficiency could unlock further upside
Key Metrics & Analysis
Financial Health
Revenue Growth-27.50%
Profit Margin-17.94%
P/E Ratio1.2
ROE-41.91%
ROA2.20%
Debt/Equity291.41
P/B Ratio-0.6
Op. Cash Flow$25.8M
Free Cash Flow$33.7M
Industry P/E37.2
Technical Analysis
TrendNeutral
RSI71.7
Support$0.52
Resistance$1.06
MA 20$0.68
MA 50$0.67
MA 200$1.60
MACDBullish
VolumeIncreasing
Fear & Greed Index90.93
Valuation
Fair Value$8.36
Target Price$3.75
Upside/Downside285.88%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.90
Volatility125.16%
Sector RiskHigh
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.